RU2708672C1 - Конъюгаты цитарабина для лечения рака - Google Patents

Конъюгаты цитарабина для лечения рака Download PDF

Info

Publication number
RU2708672C1
RU2708672C1 RU2018119319A RU2018119319A RU2708672C1 RU 2708672 C1 RU2708672 C1 RU 2708672C1 RU 2018119319 A RU2018119319 A RU 2018119319A RU 2018119319 A RU2018119319 A RU 2018119319A RU 2708672 C1 RU2708672 C1 RU 2708672C1
Authority
RU
Russia
Prior art keywords
acid
subject
administered
group
astarabine
Prior art date
Application number
RU2018119319A
Other languages
English (en)
Russian (ru)
Inventor
Стела ГЕНГРИНОВИЧ
ЯКАР Рут БЕН
Original Assignee
Биосайт Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биосайт Лтд. filed Critical Биосайт Лтд.
Application granted granted Critical
Publication of RU2708672C1 publication Critical patent/RU2708672C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
RU2018119319A 2015-12-03 2016-01-25 Конъюгаты цитарабина для лечения рака RU2708672C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562262428P 2015-12-03 2015-12-03
US62/262,428 2015-12-03
PCT/IL2016/050077 WO2017093993A1 (en) 2015-12-03 2016-01-25 Cytarabine conjugates for cancer therapy

Publications (1)

Publication Number Publication Date
RU2708672C1 true RU2708672C1 (ru) 2019-12-11

Family

ID=58796462

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018119319A RU2708672C1 (ru) 2015-12-03 2016-01-25 Конъюгаты цитарабина для лечения рака

Country Status (10)

Country Link
US (1) US11058701B2 (enExample)
EP (1) EP3383407B1 (enExample)
JP (3) JP7149183B2 (enExample)
CN (1) CN108289905A (enExample)
AU (2) AU2016362830B2 (enExample)
BR (1) BR112018011177A2 (enExample)
CA (1) CA3007058C (enExample)
IL (2) IL259631B (enExample)
RU (1) RU2708672C1 (enExample)
WO (1) WO2017093993A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
CN108431017B (zh) 2015-12-03 2021-12-21 拜欧赛特有限公司 用于癌症疗法的缀合物的盐
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
BR112020000492A2 (pt) * 2017-07-09 2020-07-14 Biosight Ltd. terapia de câncer de combinação
CN110590862A (zh) * 2019-11-01 2019-12-20 南京师范大学 阿糖胞苷4-n位氨基酸衍生物及其制备方法与应用
CN115052607A (zh) * 2020-02-04 2022-09-13 拜欧赛特有限公司 天冬阿糖胞苷药物组合物和其用途
CN115461058A (zh) * 2020-04-23 2022-12-09 拜欧赛特有限公司 用于治疗血液癌的方法和方案
JP2023541469A (ja) * 2020-09-21 2023-10-02 バイオサイト リミテッド アスパシタラビンの結晶形態
CN112409431B (zh) * 2020-12-07 2023-04-21 武汉伯瑞恒医药科技有限公司 阿糖胞苷结构类似物及其制备方法和用途
CN118434752A (zh) * 2021-11-21 2024-08-02 拜欧赛特有限公司 用于治疗癌症的基于阿糖胞苷-氨基酸的前药
WO2023175622A1 (en) * 2022-03-17 2023-09-21 Biosight Ltd. Crystalline forms of aspacytarabine
WO2023228177A1 (en) * 2022-05-22 2023-11-30 Biosight Ltd. Compositions comprising aspacytarabine and additional compounds, and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275590A1 (en) * 2004-02-02 2011-11-10 BioSight Ltd., Conjugates for cancer therapy and diagnosis
WO2014097318A2 (en) * 2012-12-18 2014-06-26 Godavari Biorefineries Limited Agents for eliminating tumour-initiating cells

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2949451A (en) 1959-04-21 1960-08-16 Hoffmann La Roche Preparation of thymidine and deoxyfluorouridine, and intermediates therefor
US3041335A (en) 1959-04-21 1962-06-26 Hoffmann La Roche Mercury salts of nitrogen heterocyclics and preparation thereof
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4296105A (en) 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4348522A (en) 1980-01-23 1982-09-07 Starks Associates, Inc. N-(phosphonacetyl)-L-aspartic acid salts with piperazine, cyclohexylamine and calcium
EP0329184A3 (en) 1988-02-19 1990-05-23 Neorx Corporation Antimers and antimeric conjugation
FI105556B (fi) 1991-09-30 2000-09-15 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten pyrimidiiniukleosidijohdannaisten valmistamiseksi, joilla on kasvaimen vastaista vaikutusta
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2180348A1 (en) * 1994-01-11 1995-07-13 Robert Plourde, Jr. Hepatocyte-targeted drug conjugates
ES2297832T3 (es) 1994-08-19 2008-05-01 La Region Wallonne Conjugados que comprenden un agente antitumoral y su utilizacion.
JPH0859688A (ja) 1994-08-25 1996-03-05 Mitsui Toatsu Chem Inc ５’−チオノエステル置換トリフルオロチミジン誘導体およびそれを有効成分とする制癌剤
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
AU2595697A (en) 1996-03-29 1997-10-22 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
NZ512171A (en) 1998-12-11 2004-07-30 Medarex Inc Prodrug compound comprising a therapeutic agent, an oligopeptide with a non-genetically encoded amino acid, a stabilizing group and optionally a linker group
AU2003286816B2 (en) 2002-10-31 2010-08-19 Metabasis Therapeutics, Inc. Novel cytarabine monophosphate prodrugs
EP2099316B1 (en) 2006-12-13 2017-06-21 Givaudan S.A. Flavour modulating derivative of a carboxylic acid and a purine, pyrimidine, nucleoside or nucleotide
CN101812105A (zh) 2009-02-25 2010-08-25 沈阳药科大学 阿糖胞苷5’-o-氨基酸酯和其盐类及其制备方法
JP5873656B2 (ja) * 2011-06-13 2016-03-01 株式会社Ihi 金属サレン錯体化合物、局所麻酔薬剤及び抗悪性腫瘍薬剤
WO2013058294A1 (ja) 2011-10-18 2013-04-25 味の素株式会社 膵臓癌及び／又は胆道癌治療薬
WO2015178265A1 (ja) 2014-05-23 2015-11-26 日本化薬株式会社 新規なグルタミン酸誘導体およびその用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275590A1 (en) * 2004-02-02 2011-11-10 BioSight Ltd., Conjugates for cancer therapy and diagnosis
WO2014097318A2 (en) * 2012-12-18 2014-06-26 Godavari Biorefineries Limited Agents for eliminating tumour-initiating cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DOHNER H., et al., Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood. 2014 Aug 28; 124(9):1426-33. doi: 10.1182/blood-2014-03-560557. Epub 2014 Jul 8. *

Also Published As

Publication number Publication date
JP2022097619A (ja) 2022-06-30
IL287644A (en) 2021-12-01
US20180369265A1 (en) 2018-12-27
CN108289905A (zh) 2018-07-17
JP2018535989A (ja) 2018-12-06
US11058701B2 (en) 2021-07-13
CA3007058A1 (en) 2017-06-08
JP2020183419A (ja) 2020-11-12
AU2022204373B2 (en) 2024-01-25
JP7417658B2 (ja) 2024-01-18
EP3383407A4 (en) 2019-07-17
JP7149183B2 (ja) 2022-10-06
CA3007058C (en) 2023-10-17
AU2022204373A1 (en) 2022-07-28
IL259631B (en) 2021-10-31
AU2016362830B2 (en) 2022-07-14
EP3383407B1 (en) 2023-12-06
EP3383407A1 (en) 2018-10-10
BR112018011177A2 (pt) 2018-11-21
WO2017093993A1 (en) 2017-06-08
IL259631A (en) 2018-07-31
AU2016362830A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
RU2708672C1 (ru) Конъюгаты цитарабина для лечения рака
US6232298B1 (en) Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
BR112020000492A2 (pt) terapia de câncer de combinação
KR100290132B1 (ko) 전신 염증 및 염증성 간염 치료용 피리미딘 누클레오티드 전구체
EP3352759A1 (en) Treatment of neurodegenerative diseases
ES2229212T3 (es) Precursores de nucleotidos de pirimidina para el tratamiento de la hepatitis inflamatoria.
US12064445B2 (en) Cytarabine conjugates for cancer therapy
US6329350B1 (en) Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
ES3009748T3 (en) Pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
TW202019440A (zh) 用於治療癌症之組合療法
CN111479572A (zh) Sstr靶向缀合物及其制剂
TW202142238A (zh) 維奈托克(venetoclax)之水溶性高分子衍生物
HK40025426A (en) Combination cancer therapy
AU2005232281A1 (en) Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
JPS6227047B2 (enExample)
AU5262499A (en) Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
AU2006236108A1 (en) Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
HK1004484B (en) Pyrimidine nucleotide precursors for treatment of inflammatory hepatitis